High-dose methotrexate and rituximab with deferred radiotherapy for newly diagnosed primary B-cell CNS lymphoma

Neuro-Oncology

Volumn 12, Issue 7, 2010, Pages 736-744

  Chamberlain, Marc C ^a   Johnston, Sandra K ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Deferred whole brain irradiation; High dose methotrexate; Primary CNS lymphoma; Rituximab; Up front therapy

Indexed keywords

METHOTREXATE; PROCARBAZINE; RITUXIMAB; TEMOZOLOMIDE;

ADULT; AGED; ANEMIA; ARTICLE; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG MEGADOSE; FATIGUE; FEMALE; HUMAN; HYPERGLYCEMIA; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PROGRESSION FREE SURVIVAL; THROMBOPHLEBITIS; TREATMENT DURATION; TUMOR LOCALIZATION; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CENTRAL NERVOUS SYSTEM NEOPLASMS; FEMALE; HUMANS; LYMPHOMA, B-CELL; MALE; METHOTREXATE; MIDDLE AGED; PROSPECTIVE STUDIES; SURVIVAL RATE; YOUNG ADULT;

EID: 78650284401     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/noq011     Document Type: Article

References (37)

1. Abrey LE, Yahalom J, DeAngelis LM. Treatment of primary CNS lymphoma: the next step. J Clin Oncol. 2000;18:3144-3150.
2. Abrey LE, Moskowitz CH, Mason WP, et al. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stemcell rescue in patients with newly diagnosed primary CNS lymphoma. J Clin Oncol. 2001;21:4151-4156.
3. Bataille B, Delwail V, Menet E, et al. Primary intracerebral malignant lymphoma: a report of 248 cases. J Neurosurg. 2000;92:261-266.
4. Batchelor TT, Carson K, O'Neill A, et al. NABTT CNS Consortium: the treatment of primary central nervous system lymphoma (PCNSL) with methotrexate and deferred radiotherapy - NABTT 96-07. J Clin Oncol. 2003;21:1044-1049.
5. Batchelor T, Loeffler JS. Primary CNS lymphoma. J Clin Oncol. 2006;24:1281-1288.
6. DeAngelis LM, Yahalom J, Thaler HT, Kher U. Combined modality therapy for primary CNS lymphoma. J Clin Oncol. 1992;10(4):635-643.
7. DeAngelis LM, Seiferheld W, Schold SC, Fisher B, Schultz CJ. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: radiation therapy oncology group 93-100. J Clin Oncol. 2002;20:4643-4648.
8. Ferreri AJ, Dell'Oro S, Foppoli M, et al. MATLLDE regimen followed by radiotherapy is an active regimen against primary CNS lymphoma. Neurology. 2006;66:1435-1438.
9. Ferreri AJ, Reni M, Pasini F, et al. A multicenter study of treatment of primary CNS lymphoma. Neurology. 2002;59:1513-1520.
10. Freilich RJ, Delattre JY, Monjour A, DeAngelis LM. Hemotherapy without radiation therapy as initial treatment for primary CNS lymphoma in older patients. Neurology. 1996;46:435-439.
11. Fisher BJ, Seiferheld W, Chultz C, et al. Secondary analysis of RTOG 9310:an intergroup Phase II combined modality treatment of primary central nervous system lymphoma with chemotherapy and hyperfractionated radiotherapy. J Neuro Oncol. 2005;74(2):201-205.
12. Gavrilovic IT, Hormgo A, Yahalom J, et al. Long-term follow-up of high dose methotrexate based therapy with or without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol. 2006;24:4570-4574.
13. Gerstner ER, Carson KA, Grossman SA, Batchelor TT. Long-term outcome in PCNSL patients treated with high-dose methotrexate and deferred radiation. Neurology. 2008;70:401-403.
14. Glass J, Gruber ML, Cher L, et al. Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long term outcome. J Neurosurg. 1994;81:188-195.
15. Herrlinger U, Schabert M, Brugger W, et al. German Cancer Society Neuro-Oncology Working group NOA-03 multicenter trial of single agent methotrexate for primary central nervous system lymphoma. Ann Neurol. 2002;51:247-252.
16. Hoang-Xuan K, Tallandier L, Chinot O, Soubeyran P, Bogdhan U, Hildebrand J. Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a Multicenter Phase II study (26952) of the European Organization for research and treatment of Cancer brain tumor group. J Clin Oncol. 2003;21:2726-2731.
17. Illerhaus G, Marks R, Ihorst G, et al. High-dose chemotherapy with autologous stem cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J Clin Oncol. 2006;24:3865-3870.
18. Lachance DH, O'Neill BP, MacDonald DR, Jaeckle K, Witzig T, Li C. Primary leptomeningeal lymphoma: report of 9 cases, diagnosis with immunocytochemical analysis, and review of the literature. Neurology. 1991;41:95-100.
19. Nelson DF, Martz KL, Bonner H, et al. Non-Hodgkin's lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on the prospective trial by Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Rad Oncol Biol Phys. 1992;23:9-17.
20. Neuwelt EA, Goldman DL, Dahlborg SA, et al. Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: prolonged survival and preservation of cognitive function. J Clin Oncol 1991;9(9): 1580-1590.
21. Pels H, Schmidt-Wolf IG, Glasmacher A, et al. Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol. 2003;21:4489-4495. (Pubitemid 46594018)
22. Plotkin SR, Betensky RA, Hochberg FH, et al. Treatment of primary central nervous system lymphoma with sequential courses of high-dose methotrexate. Clin Cancer Res. 2004;10:5643-5646.
23. Poortmans PMP, Kluin-Nelemans HC, Haaxma-Reiche H, et al. High-dose methotrexate based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: european organization for research and treatment of cancer Lymphoma Group Phase II trial 20962. J Clin Oncol. 2003;21:4483-4488.
24. Shah GD, Yahalom J, Correa DD, et al. Combined immunochemotherapy with reduced whole brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol. 2007;25(30):4730-4735. (Pubitemid 350086474)
25. Shibamoto Y, Ogino H, Hassegawa M, Suzuki K, Nishio M, Fujii T. Results of radiation monotherapy for primary central nervous system lymphoma in the 1990s. Int J Radiat Oncol Biol Phys. 2005;62:809-813. (Pubitemid 40779773)
26. Velasquez WS. Primary central nervous system lymphoma. J Neuro-Oncol. 1994;20:177-185.
27. Balmaceda C, Gaynor JJ, Sun M, Gluck J, DeAngelis L. Leptomeningeal tumor in primary central nervous system lymphoma: recognition, significance, and implications. Ann Neurol. 1995;38:202-209.
28. Chamberlain MC, Kormanik P, Glantz M. Recurrent primary central nervous system lymphoma complicated by lymphomatous meningitis. Oncology Reports. 1998;5:521-523.
29. MacDonald DR, Cascino TL, Schold SC, Cairncross JG. Response criteria for phase 2 studies of supratentorial malignant glioma. J Clin Oncol. 1990;8:1277-1280.
30. Abrey LE, Batchelor TT, Ferreri AJ, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol. 2005;23:5034-5043.
31. Widemann BC, Balis FM, Murphy RF, et al. Carboxypeptidase-G2, thymidine, and leucovorin rescue in cancer patients with methotrexateinduced renal dysfunction. J Clin Oncol. 1997;15(5): 2125-2134.
32. Abrey LE, Ben-Porat L, Panageas KS, et al. Primary central nervous system lymphoma: the Memorial-Sloan Kettering Cancer Center prognostic model. J Clin Oncol. 2006;24:5711-5715.
33. Fischer L, Thiel E, Klasen H-A, et al. Prospective trial on topotecan salvage therapy in primary CNS lymphoma. Ann Oncol. 2006;17:1141-1145.
34. Herrlinger U, Brugger W, Bamberg M, Kuker W, Dichgans J, Weller M. PCV salvage chemotherapy for recurrent primary CNS lymphoma. Neurology. 2000;54:1707-1709.
35. Hottinger AF, DeAngelis LM, Yahalom J, Abrey L. Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma. Neurology. 2007;69:1178-1182.
36. Reni M, Zaja F, Mason W, et al. Temozolomide as salvage treatment in primary brain lymphoma. Br J Cancer. 2007;96:864-867.
37. Soussain C, Suzan F, Hoang-Xuan K, et al. Results of intensive chemotherapy followed by hematopoetic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol. 2001;19:742-749.